Jefferson Health

Physician Profile

Serge Jabbour, MD, FACP, FACE

Jefferson University Physician

Academic Title: Professor
Division Director, Endocrinology
Director, Diabetes Center
Director, Comprehensive Weight Management Program

Specialties
Endocrinology/Diabetes & Metabolism
Endocrinology/Diabetes & Metabolism - Thyroid & Parathyroid
Endocrinology/Diabetes & Metabolism - Weight Management

Make An Appointment

Click to call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

Philadelphia
Walnut Towers, Suite 600
211 S. 9th Street
Philadelphia PA 19107
Phone: (215) 955-1925
Fax: (215) 928-3160

Medical Services

Years in Practice

17

Board Certifications

  • Internal Medicine
  • Endocrinology, Diabetes & Metabolism

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital
  • Methodist Hospital Division of Thomas Jefferson University Hospital

Awards and Honors

Philadelphia Magazine's Top Docs 2016,2015,2014,2013,2012,2011

Education

  • St. Joseph's University, Beirut, Lebanon, Medical School

Internship

  • Cooper Medical Center, Camden, NJ

Residency

  • Cooper Medical Center, Camden, NJ

Fellowship

  • Thomas Jefferson University Hospital

Recent Publications

Musculoskeletal manifestations of primary hyperparathyroidism

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial

SGLT2 inhibitors

Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: A 24-week, multicenter, randomized, double-blind, placebo-controlled study

Dapagliflozin in type 2 diabetes: Effectiveness across the spectrum of disease and over time

An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients

Dapagliflozin is effective as add-on therapy to sitagliptin with or withoutmetformin: A 24-Week, multicenter, randomized, double-blind, placebo-controlled study

SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: A new approach to an old problem

Comment and response to: Dapagliflozin-do we need it registered for type 2 diabetes?

Collaboration designed to increase translation of diabetes research outcomes into clinical practice

Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor Dapagliflozin

Stop metformin before elective surgery or intravascular contrast dye study to decrease the risk of lactic acidosis

Consider insulin therapy to correct perioperative hyperglycemia in both diabetic and nondiabetic patients

Subclinical hyperthyroidism: Current concepts and scintigraphic imaging

Exenatide once weekly in type 2 diabetes mellitus

Sodium Glucose Cotransporter 2 Inhibitors

Management of diabetes mellitus in the elderly

Advantages of extended-release metformin in patients with type 2 diabetes mellitus

46, XX SRY-positive male syndrome presenting with primary hypogonadism in the setting of scleroderma

Skin manifestations of hormone-secreting tumors